Therapeutic Potential of Fosmanogepix (APX001) for Intra-abdominal Candidiasis: from Lesion Penetration to Efficacy in a Mouse Model [PDF]
Antimicrobial Agents and Chemotherapy, 2021 Intra-abdominal candidiasis (IAC) is one of the most common yet underappreciated forms of invasive candidiasis. IAC is difficult to treat, and therapeutic failure and drug-resistant breakthrough infections are common in some institutions despite the use ...
Matthew Zimmerman +2 more
exaly +6 more sources
APX001 Is Effective in the Treatment of Murine Invasive Pulmonary Aspergillosis [PDF]
Antimicrobial Agents and Chemotherapy, 2019 Invasive pulmonary aspergillosis (IPA) due to Aspergillus fumigatus is a serious fungal infection in the immunosuppressed patient population. Despite the introduction of new antifungal agents, mortality rates remain high, and new treatments are needed ...
Teclegiorgis Gebremariam +2 more
exaly +10 more sources
678. Galactomannan Is a Biomarker of APX001 (Fosmanogepix) Efficacy in Treating Experimental Invasive Pulmonary Aspergillosis [PDF]
Open Forum Infectious Diseases, 2019 Background Invasive pulmonary aspergillosis (IPA) is a serious fungal infection afflicting immunocompromised patients. Galactomannan (GM) detection in biological samples using the Platelia ELISA has been shown to predict therapy response by azoles, and ...
Abdullah Alqarihi
exaly +5 more sources
Galactomannan Is a Biomarker of Fosmanogepix (APX001) Efficacy in Treating Experimental Invasive Pulmonary Aspergillosis [PDF]
Antimicrobial Agents and Chemotherapy, 2019 Galactomannan (GM) detection in biological samples has been shown to predict therapeutic response by azoles and polyenes. In a murine invasive pulmonary aspergillosis model, fosmanogepix or posaconazole treatment resulted in an ∼6- to 7-log reduction in ...
Teclegiorgis Gebremariam +2 more
exaly +8 more sources
1340. Population Pharmacokinetic (PK) Analysis of APX001 Using Phase 1 Data [PDF]
Open Forum Infectious Diseases, 2018 Background APX001 is a novel antifungal agent which is rapidly converted to the active metabolite APX001A. APX001A exhibits in vitro activity against many clinically important yeast and fungi, including echinocandin- and azole-resistant Candida species ...
Trang M +6 more
exaly +8 more sources
Efficacy and Pharmacokinetics of Fosmanogepix (APX001) in the Treatment of Candida Endophthalmitis and Hematogenous Meningoencephalitis in Nonneutropenic Rabbits. [PDF]
Antimicrob Agents Chemother, 2021 Candida endophthalmitis is a serious sight-threatening complication of candidemia that may occur before or during antifungal therapy. Hematogenous Candida meningoencephalitis (HCME) is also a serious manifestation of disseminated candidiasis in premature
Petraitiene R +7 more
europepmc +5 more sources
Safety and Pharmacokinetics of Intravenous and Oral Fosmanogepix, a First-in-Class Antifungal Agent, in Healthy Volunteers [PDF]
Antimicrobial Agents and Chemotherapy, 2023 Fosmanogepix (FMGX, APX001), a first-in-class, intravenous (i.v.) and oral (p.o.) antifungal prodrug candidate is currently in clinical development for the treatment of invasive fungal infections.
Abhijeet Jakate, Margaret Tawadrous
exaly +3 more sources
Efficacy of APX2039 in a Rabbit Model of Cryptococcal Meningitis [PDF]
mBio, 2022 Cryptococcal Meningitis (CM) is uniformly fatal if not treated, and treatment options are limited. We previously reported on the activity of APX2096, the prodrug of the novel Gwt1 inhibitor APX2039, in a mouse model of CM.
Charles D. Giamberardino +14 more
doaj +4 more sources
Reason and reality-identifying barriers to patient enrolment for clinical trials in invasive candidiasis. [PDF]
J Antimicrob Chemother, 2022 Objectives Enrolment of subjects to clinical trials investigating novel drugs for infectious diseases is an ongoing challenge. In this study, we evaluate factors associated with non-enrolment in treatment trials for invasive candidiasis.
Sprute R +3 more
europepmc +2 more sources
Emerging and future strategies in the management of recalcitrant Candida auris. [PDF]
Med Mycol, 2022 Candida auris is an emerging, multi drug resistant fungal pathogen that has caused infectious outbreaks in over 45 countries since its first isolation over a decade ago, leading to in-hospital crude mortality rates as high as 72%.
Bandara N, Samaranayake L.
europepmc +5 more sources